Plain-English translation of NCT06916624 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a new type of imaging scan called 18F-NY104 PET/CT that may help doctors better detect and monitor kidney cancer. The scan uses a special tracer designed to highlight cancer cells in the body, making it easier to see where the disease is located. Researchers hope this new imaging approach will help improve how kidney cancer is diagnosed and tracked over time.
Currently, kidney cancer can be difficult to detect early and to monitor after treatment, and some patients develop cancer spread (metastasis) even after surgery. This trial exists to see whether this new imaging approach could help doctors identify kidney cancer more accurately and catch it earlier, which might improve patient outcomes.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the new 18F-NY104 PET/CT imaging scan at the hospital. The scan involves receiving an injection of the tracer and then being scanned by the PET/CT machine to create detailed images of your body. The trial involves about 40 participants total across multiple hospital centers, and your participation will help researchers understand whether this new imaging approach works better for detecting kidney cancer.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China
Sponsor
The Affiliated Hospital of Qingdao University
Collaborators
Qianfoshan Hospital, Weifang People's Hospital
Enrollment target
~40 participants
Started
April 2025
Primary completion
December 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
guang Zhen Wang
The Affiliated Hospital of Qingdao University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.